

27 April 2026

BPH Strengthens Commercialisation Strategy with Appointment of Chief Scientific Officer

Highlights

- **Appointment of Ms Ifat Mazouz as full time Chief Scientific Officer (CSO).**
- **Transition from part-time Advisory Board role to executive leadership, assuming control of the Company's R&D programs.**
- **Highly experienced aquaculture and marine biotechnology executive with a proven track record in commercialising R&D into scalable, market-ready products.**
- **Appointment significantly enhances BPH's ability to convert its R&D portfolio into revenue-generating opportunities.**
- **Immediate focus on advancing key projects, including finalisation of the Company's kefir drink product in powdered form.**
- **New CSO to collaborate closely with Company's R&D consultants driving execution and commercial outcomes.**

Appointment of Chief Scientific Officer

The Board of BPH Global Ltd (ASX: BP8) (**BPH, BPH Global or Company**) is pleased to announce the appointment of Ms Ifat Mazouz as Chief Scientific Officer (CSO), effective from 25 May 2026.

Ms Mazouz transitions into this executive role from her current position as a member of the Company's Advisory Board, where she has been contributing to the strategic assessment and commercial alignment of BPH's research initiatives. Her appointment reflects the Company's strategic focus on accelerating the commercialisation of its R&D portfolio and ensuring that all research programs are aligned with clearly defined pathways to market, scalability, and revenue generation.

Ms Mazouz brings nearly two decades of international experience across marine biotechnology, aquaculture systems, and product development, with particular expertise in translating R&D programs from concept through to commercial deployment.

Driving Commercial Outcomes from R&D

As CSO, Ms Mazouz will assume full responsibility for the leadership, coordination, and execution of the Company's research and development activities, with a strong mandate to deliver commercial outcomes.

Her role will include:

- Leading the progression of priority R&D projects toward near-term commercialisation, including the Company's kefir drink product in powdered form;
- Overseeing both in-house and outsourced R&D programs to ensure alignment with commercial objectives;
- Acting as the primary liaison between BP8 and its R&D partners;

- Identifying and advancing new opportunities with strong commercial potential; and
- Supporting investor engagement and capital markets initiatives through clear articulation of the commercial value of BPH Global's technologies.

This structure is designed to ensure that BPH's R&D activities are tightly integrated with commercial strategy, enabling efficient transition from scientific development to market-ready products.

Managing Director Mathew Leonard commented, "Ms Azouz' appointment is yet another key milestone that BPH Global has achieved over past months, and illustrates our commitment to becoming the pre-eminent company in seaweed innovation and commercialisation. We are so pleased to welcome Ms Azouz at the commencement of what I firmly believe will be a successful period of innovation and growth for our Company and I look forward to updating shareholders with more positive news in coming months."

Transition to Australian-Based Role

The Company intends for Ms Mazouz to be based in Melbourne, Australia in her role as CSO.

As Ms Mazouz does not currently hold Australian working rights, the Company will undertake the process of applying for and obtaining an appropriate work visa on her behalf. Upon the grant of the visa (Visa Date), Ms Mazouz will relocate to Australia as soon as practicable.

At that time, the interim consultancy arrangement will be replaced by a formal executive employment agreement under which Ms Mazouz will serve as Chief Scientific Officer based in Australia. During the interim period, Ms Mazouz will be based in Southeast Asia while performing her role.

– ENDS –

Authorised for release by:

The Board of BPH Global Ltd
www.bphglobal.com

Media and Investor Relations:

Peter Taylor

peter@nwrcommunications.com.au